ArticleCancer research and treatment2026

Differences in Responses to Neoadjuvant Anti-HER2 Therapy between HER2 2+/ISH+ and HER2 3+ in HER2-Positive Breast Cancer.

Lingjun Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.